Some subjects who participate in trials of novel therapies mistakenly believe that the trial is designed in a way to maximize benefit to the individual subjects—thus laboring under the Therapeutic Misconception. Patients with ALS have a uniformly fatal disease, and one might worry that ALS patients are even more prone to the therapeutic misconception.
Watch as our speakers discuss the evidence for a therapeutic misconception in ALS trials, and consider more broadly how the therapeutic misconception should be addressed by investigators and institutional review boards.
Scott Kim, MD, PhD Department of Bioethics, National Institutes of Health
James D. Berry, MD, MPH Unit Chief, ALS Multidisciplinary Clinic, Massachusetts General Hospital
Spencer Hey, PhD, Research Fellow, Brigham and Women's Hospital Instructor, Center for Bioethics Harvard Medical School